Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06503263
PHASE2

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Sponsor: Navy General Hospital, Beijing

View on ClinicalTrials.gov

Summary

The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.

Official title: Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma

Key Details

Gender

All

Age Range

14 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2024-08-30

Completion Date

2030-12-30

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DRUG

Zanubrutinib plus Lenalidomide as Maintenance Therapy

Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay

Locations (1)

Navy General Hospital

Beijing, Beijing Municipality, China